Literature DB >> 8814475

Resolution of recurrent atelectasis in spinal cord injury patients with administration of recombinant human DNase.

K G Voelker1, K G Chetty, C K Mahutte.   

Abstract

Atelectasis occurs frequently in patients with spinal cord injury (SCI). Impaired cough leads to ineffective clearance of secretions. If the secretions cannot be cleared and become thick and purulent, atelectasis may occur. Recombinant human DNase (rhDNase) has been shown to decrease purulent sputum viscosity in vitro. We report two SCI patients with respiratory failure due to recurrent atelectasis from purulent secretions in whom conventional treatment methods had failed. Administration of rhDNase resulted in successful resolution of atelectasis. These results suggest the need for a controlled clinical trial.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8814475     DOI: 10.1007/bf01708100

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


  9 in total

Review 1.  Respiratory complications and management of spinal cord injuries.

Authors:  J K Mansel; J R Norman
Journal:  Chest       Date:  1990-06       Impact factor: 9.410

2.  Pus, deoxyribonucleic acid, and sputum viscosity.

Authors:  R Picot; I Das; L Reid
Journal:  Thorax       Date:  1978-04       Impact factor: 9.139

3.  Atelectasis and pneumonia in acute spinal cord injury.

Authors:  M J Fishburn; R J Marino; J F Ditunno
Journal:  Arch Phys Med Rehabil       Date:  1990-03       Impact factor: 3.966

4.  Recombinant human DNase I reduces the viscosity of cystic fibrosis sputum.

Authors:  S Shak; D J Capon; R Hellmiss; S A Marsters; C L Baker
Journal:  Proc Natl Acad Sci U S A       Date:  1990-12       Impact factor: 11.205

5.  Cause of death for patients with spinal cord injuries.

Authors:  M J DeVivo; P L Kartus; S L Stover; R D Rutt; P R Fine
Journal:  Arch Intern Med       Date:  1989-08

6.  Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group.

Authors:  H J Fuchs; D S Borowitz; D H Christiansen; E M Morris; M L Nash; B W Ramsey; B J Rosenstein; A L Smith; M E Wohl
Journal:  N Engl J Med       Date:  1994-09-08       Impact factor: 91.245

7.  Incidence of respiratory complications following spinal cord injury.

Authors:  A B Jackson; T E Groomes
Journal:  Arch Phys Med Rehabil       Date:  1994-03       Impact factor: 3.966

8.  Atelectasis in spinal cord injured people after initial medical stabilization.

Authors:  B Sugarman
Journal:  J Am Paraplegia Soc       Date:  1985-07

9.  Pulmonary dysfunction following traumatic quadriplegia. Recognition, prevention, and treatment.

Authors:  J C McMichan; L Michel; P R Westbrook
Journal:  JAMA       Date:  1980-02-08       Impact factor: 56.272

  9 in total
  4 in total

Review 1.  Physiotherapy secretion removal techniques in people with spinal cord injury: a systematic review.

Authors:  W Darlene Reid; Jennifer A Brown; Kristin J Konnyu; Jennifer M E Rurak; Brodie M Sakakibara
Journal:  J Spinal Cord Med       Date:  2010       Impact factor: 1.985

2.  Recombinant human deoxyribonuclease improves atelectasis in mechanically ventilated children with cardiac disease.

Authors:  Parthak Prodhan; B Greenberg; Adnan T Bhutta; Carrie Hyde; Ajay Vankatesan; Michiaki Imamura; Robert Db Jaquiss; Umesh Dyamenahalli
Journal:  Congenit Heart Dis       Date:  2009 May-Jun       Impact factor: 2.007

3.  DNase and atelectasis in non-cystic fibrosis pediatric patients.

Authors:  Tom Hendriks; Matthijs de Hoog; Maarten H Lequin; Annick S Devos; Peter J F M Merkus
Journal:  Crit Care       Date:  2005-05-20       Impact factor: 9.097

4.  Use of recombinant human deoxyribonuclease in pediatric intensive care unit - a single-center experience.

Authors:  Daniel Meireles; Sofia Ribeiro Fernandes; Alzira Sarmento; Telma Barbosa; Manuel Ferreira Magalhães; Ana Ramos; Paula Cristina Fernandes
Journal:  Rev Paul Pediatr       Date:  2021-09-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.